Investors of record on Friday, June 1st will be paid a $0.18 dividend. The ratio fall due to Abaxis, Inc. positioning: 12 sold and 40 reduced. 25 funds bought stakes and 41 increased stakes. (NASDAQ:ABAX). Glenmede Tru Communication Na reported 88 shares or 0% of all its holdings. D E Shaw stated it has 0% of its portfolio in Abaxis, Inc.
Fifth Third Comml Bank has invested 0% in Abaxis, Inc.
Several analysts have released their opinion on Abaxis, Inc. (NASDAQ:ABAX). Piedmont Limited Com accumulated 4,665 shares. 4,076 are owned by Peak6 Investments Lp.
On 1/25/2018 NASDAQ:ABAX - Abaxis announced a quarterly dividend of $0.16 0.91% with an ex dividend date of 2/28/2018 which will be payable on 3/15/2018. (NASDAQ:ABAX). Ubs Asset Mgmt Americas Inc holds 4,380 shs. Barclays Pcl reported 0% of its portfolio in Abaxis, Inc.
Since January 30, 2018, it had 0 buys, and 10 selling transactions for $2.85 million activity. (NASDAQ:ABAX). EVENHUIS HENK also sold $333,460 worth of Abaxis, Inc. Abaxis had 10 analyst reports since November 30, 2017 according to SRatingsIntel. 08, 2018. These shares are worth $408,360 and were traded at $68.06 each. 1,650 shs valued at $122,652 were sold by TOCKMAN CRAIG on Wednesday, January 31. The SEC filing shows that Casey Michael D performed a sale of 5,000 shares. (NASDAQ:ABAX). C M Bidwell & Associate Limited has invested 0% of its portfolio in Abaxis, Inc. Abaxis, Inc. (NASDAQ:ABAX) has $1.88 billion market cap. The company's valuation will be $94.05 million more at $87.02 PT.
On the other hand the company has Relative Strength Index (RSI 14) of 75.7 along with Average True Range (ATR 14) of 2.79, Consequently Abaxis Inc (NASDAQ:ABAX)'s weekly and monthly volatility is 2.44%, 3.18% respectively. ABAX is uptrending and has moved 44.47% since May 17, 2017.
Analysts are expecting average earnings estimates of $0.36 for the current quarter based on the opinion of 8 analysts, relating to high earnings per share estimates of $0.43 and low estimates of $0.32, however Abaxis Inc (NASDAQ:ABAX) reported $0.28 earnings per share for the same quarter previous year. ABAX's profit will be $7.95 million for 59.53 P/E if the $0.35 EPS becomes a reality. The company reported the earnings of $0.42/Share in the last quarter where the estimated EPS by analysts was $0.31/share.
Some buy side analysts are also providing their Analysis on Abaxis, Inc., where 1 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 1 said it's a HOLD, and 0 analysts rated the stock as Sell. The positive are 14%. The firm has $90.0 highest while $48 is the lowest target price. The average target $65 is -21.57% below the last ($82.88) price.
Abaxis has higher earnings, but lower revenue than Cubic. The company rating was downgraded by Sidoti on Wednesday, May 16. On Tuesday, January 9 Northcoast maintained the shares of ABAX in report with "Buy" rating. On Friday, January 26 the firm has "Hold" rating given by Stephens. On Monday, January 29 the rating was maintained by Canaccord Genuity with "Hold". (NASDAQ:ABAX) with "Hold" rating. On Tuesday, January 9 the firm has "Hold" rating by Raymond James given. On Thursday, January 25 the stock of Abaxis, Inc. The stock rating was maintained by Northcoast with "Buy" on Monday, January 29.
Abaxis recently launched its new VetScan FLEX4 Rapid Test, which is meant to help detect diseases, such as Heartworm, Lyme, Ehrlichia, and Anaplasma, in dogs. (NASDAQ:ABAX) with "Hold" rating. The titles are as follows: "M&A daily wrap: NFL's Carolina Panthers, Cam Newton, David Tepper, Appaloosa, Brynwood Partners" brought out on May 16, 2018, "INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Abaxis ..." on May 16, 2018, "26 Stocks Moving In Wednesday's Pre-Market Session" with a publish date: May 16, 2018, "Are Abaxis Shareholders Getting Enough in the Buyout?" and the last "A Preview Of Abaxis Q4 Earnings" with publication date: April 26, 2018.